DANGEROUS AND UNDESIRABLE DRUG INTERACTIONSOF STATINS IN PATIENTS WITH CARDIOVASCULAR DISEASE

Abstract

Relevance. Antihypercholesterolemic drugs from the group of statins have a significant impact on the metabolism of the
human body. Consideration of pharmacokinetic features of statins and drug interaction with drugs of this group is an
important aspect of their safe use. Drugs administered simultaneously with statins may be inducers or inhibitors (substrates)
of CYP3A4/A5 cytochrome P450 liver isoenzymes, which should be considered in daily clinical practice in the management
of this category of patients
The aim was to study the frequency and structure of the appointment of unwanted combinations of statins with other
drugs in Semey.
Materials and methods. Design: cross-sectional study. The study included 2790 outpatient records of patients with
diagnosis: Coronary heart disease with concomitant hypercholesterolemia. The frequency of simultaneous administration of
statins with other drugs was analyzed. We took into account the peculiarities of their interaction at the level of metabolism of cytochrome P450 CYP3 isoenzymes AND transport systems of proteins-transporters of P-glycoprotein and OATR1B and to
identify potentially dangerous and significant drug combinations.
Methods of descriptive statistics are used. Numerical analysis of statistical significance was not carried out due to lack of
necessity.
Research result. Our study revealed the presence of undesirable and dangerous combinations in the majority of
patients receiving statin therapy (63.7%). The frequency of very dangerous combinations in the study was relatively low (7
cases, 0.25%). In 72.5% of cases, we did not find safety monitoring in cases where it is recommended to take statins with
caution and under the control of biochemical and other indicators.
Conclusion. We have determined a fairly high frequency of the appointment of undesirable combinations of statins with
other drugs that have competitive metabolism at the level of CYP3A, OATP1B1 and P-glycoprotein in absolute terms and
compared with the data of studies conducted in developed countries.